Pharmacogenetically tailored treatments for heart disease

Elizabeth Vafiadaki, Demetrios A. Arvanitis, Evangelia G. Kranias, Despina Sanoudou

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Heart disease represents the primary cause of death worldwide, with mortality rates being predicted to remain constant within the next couple of decades. Cardiac disease treatment currently includes the administration of drugs, predominantly aiming at improving heart performance, through controlling heart rhythm, blood pressure, as well as reducing cholesterol and blood clotting. Despite, however, the medical advances that have led towards a better understanding of heart disease pathophysiology and the development of new therapeutic approaches, the degree of success of the available drug therapies varies among patients. Polymorphisms in a number of genes have been shown to result in differences in pharmacokinetics, pharmacodynamics and drug metabolism and have therefore been associated with response to drug treatment. The occurrence of adverse drug reactions represents another factor influencing the outcome of therapeutic treatments. While the influence of genetic polymorphisms in patient's response to heart disease drugs is being unveiled, the rapidly evolving field of pharmacogenetics is promising to aid clinicians in choosing the best suited drug/dose for each patient and the pharmaceutical companies in the design of better targeted, more effective new chemical compounds. In the near future individualized, targeted therapy will become part of clinical care routine maximizing patient therapeutic benefits and minimizing risks of adverse effects.

Original languageEnglish
Pages (from-to)2194-2213
Number of pages20
JournalCurrent Pharmaceutical Design
Volume16
Issue number20
DOIs
Publication statusPublished - 20 Aug 2010
Externally publishedYes

Fingerprint

Heart Diseases
Pharmaceutical Preparations
Therapeutics
Pharmacogenetics
Blood Coagulation
Genetic Polymorphisms
Drug-Related Side Effects and Adverse Reactions
Cause of Death
Pharmacokinetics
Cholesterol
Blood Pressure
Drug Therapy
Mortality
Genes

Keywords

  • Adverse drug reactions
  • Cardiac disease
  • Drug response
  • Genetic polymorphism
  • Pharmacogenetics

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Vafiadaki, E., Arvanitis, D. A., Kranias, E. G., & Sanoudou, D. (2010). Pharmacogenetically tailored treatments for heart disease. Current Pharmaceutical Design, 16(20), 2194-2213. https://doi.org/10.2174/138161210791792796

Pharmacogenetically tailored treatments for heart disease. / Vafiadaki, Elizabeth; Arvanitis, Demetrios A.; Kranias, Evangelia G.; Sanoudou, Despina.

In: Current Pharmaceutical Design, Vol. 16, No. 20, 20.08.2010, p. 2194-2213.

Research output: Contribution to journalArticle

Vafiadaki, E, Arvanitis, DA, Kranias, EG & Sanoudou, D 2010, 'Pharmacogenetically tailored treatments for heart disease', Current Pharmaceutical Design, vol. 16, no. 20, pp. 2194-2213. https://doi.org/10.2174/138161210791792796
Vafiadaki, Elizabeth ; Arvanitis, Demetrios A. ; Kranias, Evangelia G. ; Sanoudou, Despina. / Pharmacogenetically tailored treatments for heart disease. In: Current Pharmaceutical Design. 2010 ; Vol. 16, No. 20. pp. 2194-2213.
@article{40edef9ed60f4ce191ab8b0e9848fabd,
title = "Pharmacogenetically tailored treatments for heart disease",
abstract = "Heart disease represents the primary cause of death worldwide, with mortality rates being predicted to remain constant within the next couple of decades. Cardiac disease treatment currently includes the administration of drugs, predominantly aiming at improving heart performance, through controlling heart rhythm, blood pressure, as well as reducing cholesterol and blood clotting. Despite, however, the medical advances that have led towards a better understanding of heart disease pathophysiology and the development of new therapeutic approaches, the degree of success of the available drug therapies varies among patients. Polymorphisms in a number of genes have been shown to result in differences in pharmacokinetics, pharmacodynamics and drug metabolism and have therefore been associated with response to drug treatment. The occurrence of adverse drug reactions represents another factor influencing the outcome of therapeutic treatments. While the influence of genetic polymorphisms in patient's response to heart disease drugs is being unveiled, the rapidly evolving field of pharmacogenetics is promising to aid clinicians in choosing the best suited drug/dose for each patient and the pharmaceutical companies in the design of better targeted, more effective new chemical compounds. In the near future individualized, targeted therapy will become part of clinical care routine maximizing patient therapeutic benefits and minimizing risks of adverse effects.",
keywords = "Adverse drug reactions, Cardiac disease, Drug response, Genetic polymorphism, Pharmacogenetics",
author = "Elizabeth Vafiadaki and Arvanitis, {Demetrios A.} and Kranias, {Evangelia G.} and Despina Sanoudou",
year = "2010",
month = "8",
day = "20",
doi = "10.2174/138161210791792796",
language = "English",
volume = "16",
pages = "2194--2213",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "20",

}

TY - JOUR

T1 - Pharmacogenetically tailored treatments for heart disease

AU - Vafiadaki, Elizabeth

AU - Arvanitis, Demetrios A.

AU - Kranias, Evangelia G.

AU - Sanoudou, Despina

PY - 2010/8/20

Y1 - 2010/8/20

N2 - Heart disease represents the primary cause of death worldwide, with mortality rates being predicted to remain constant within the next couple of decades. Cardiac disease treatment currently includes the administration of drugs, predominantly aiming at improving heart performance, through controlling heart rhythm, blood pressure, as well as reducing cholesterol and blood clotting. Despite, however, the medical advances that have led towards a better understanding of heart disease pathophysiology and the development of new therapeutic approaches, the degree of success of the available drug therapies varies among patients. Polymorphisms in a number of genes have been shown to result in differences in pharmacokinetics, pharmacodynamics and drug metabolism and have therefore been associated with response to drug treatment. The occurrence of adverse drug reactions represents another factor influencing the outcome of therapeutic treatments. While the influence of genetic polymorphisms in patient's response to heart disease drugs is being unveiled, the rapidly evolving field of pharmacogenetics is promising to aid clinicians in choosing the best suited drug/dose for each patient and the pharmaceutical companies in the design of better targeted, more effective new chemical compounds. In the near future individualized, targeted therapy will become part of clinical care routine maximizing patient therapeutic benefits and minimizing risks of adverse effects.

AB - Heart disease represents the primary cause of death worldwide, with mortality rates being predicted to remain constant within the next couple of decades. Cardiac disease treatment currently includes the administration of drugs, predominantly aiming at improving heart performance, through controlling heart rhythm, blood pressure, as well as reducing cholesterol and blood clotting. Despite, however, the medical advances that have led towards a better understanding of heart disease pathophysiology and the development of new therapeutic approaches, the degree of success of the available drug therapies varies among patients. Polymorphisms in a number of genes have been shown to result in differences in pharmacokinetics, pharmacodynamics and drug metabolism and have therefore been associated with response to drug treatment. The occurrence of adverse drug reactions represents another factor influencing the outcome of therapeutic treatments. While the influence of genetic polymorphisms in patient's response to heart disease drugs is being unveiled, the rapidly evolving field of pharmacogenetics is promising to aid clinicians in choosing the best suited drug/dose for each patient and the pharmaceutical companies in the design of better targeted, more effective new chemical compounds. In the near future individualized, targeted therapy will become part of clinical care routine maximizing patient therapeutic benefits and minimizing risks of adverse effects.

KW - Adverse drug reactions

KW - Cardiac disease

KW - Drug response

KW - Genetic polymorphism

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=77955632269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955632269&partnerID=8YFLogxK

U2 - 10.2174/138161210791792796

DO - 10.2174/138161210791792796

M3 - Article

VL - 16

SP - 2194

EP - 2213

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 20

ER -